Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma announced the publication of pivotal Phase 3 ENVISION trial results for ZUSDURI, their mitomycin-based treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial showed a 72.2% probability of remaining event-free at 24 months after complete response, marking the first FDA-approved n…